{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005006","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.129461+00:00","generated_at":"2026-05-28T02:52:21.081096+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neuronetics reports preliminary Q4 revenue $22.1M, FY2024 $74.5M; issues 2025 guidance with 12-19% growth","bullets":["Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).","Closed acquisition of Greenbrook TMS Dec 9, 2024; expects over $22M annualized cost synergies.","FY2025 revenue guidance $145M-$155M, pro forma growth 12-19%; gross margin ~55%.","Expects cash flow breakeven in Q3 2025; reduced cash burn in H1 2025.","Launched Better Me Provider program with over 350 sites; FDA clearance for adolescent MDD expanded TAM by 35%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005006","json":"https://secwatch.observer/filing/0001193125-25-005006.json","markdown":"https://secwatch.observer/filing/0001193125-25-005006.md","text":"https://secwatch.observer/filing/0001193125-25-005006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525005006/0001193125-25-005006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525005006/d925718d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:52:21.081096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}